Insider · CIK 0001191229
Argeris N Karabelas
Files at RGNX (REGENXBIO Inc.). First filing -, latest -.
In brief
Argeris N Karabelas files SEC Form 4 as director at RGNX (REGENXBIO Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Argeris N Karabelas has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 29, 2026 | RGNX REGENXBIO Inc. | AGrant or award Common Stock | +9,807 | $0.00 | $0 | 28,861 | Jun 2, 2026 |
| May 29, 2026 | RGNX REGENXBIO Inc. | AGrant or award Stock Options (Right to Buy)derivative | +46,600 | $0.00 | $0 | 46,600 | Jun 2, 2026 |
| May 30, 2025 | RGNX REGENXBIO Inc. | AGrant or award Common Stock | +7,768 | $0.00 | $0 | 19,054 | Jun 3, 2025 |
| May 30, 2025 | RGNX REGENXBIO Inc. | AGrant or award Stock Options (Right to Buy)derivative | +39,815 | $0.00 | $0 | 39,815 | Jun 3, 2025 |
Questions about Argeris N Karabelas
Answered from the filings on this page, as of the latest one.
Is Argeris N Karabelas buying or selling?
Argeris N Karabelas has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Argeris N Karabelas's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Argeris N Karabelas has 0.
Where does Argeris N Karabelas file Form 4?
Argeris N Karabelas has filed Form 4 at RGNX (REGENXBIO Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.